AURKA and prostate adenocarcinoma: Oncogenic drivers, including Aurora kinase A (AURKA) and MYCN, further promote the transition from prostate adenocarcinoma to NEPC by stabilizing neuroendocrine transcriptional regulators and disrupting epithelial lineage commitment [16].